Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (25.17%) | 0.00% | — | — | ||
ROIC |
(36.38%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(15.53%) | 0.00% | 0.00% | — | |
Average Days of Receivables |
87.65 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.83) | (8.66) | 0.00 | 0.00 | |
Free Cash Flow |
(107.53) | (106.18) | (143.40) | — | |
Capital Expenditures |
(10.37) | (7.28) | (9.63) | — | |
| Other line items | |||||
Cash ROIC |
(18.77%) | (54.04%) | (123.78%) | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
133.97 | 0.00 | 0.00 | — | |
Days of Inventory on Hand |
441.16 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
51.98% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
53.67% | — | — | — | |
Share Based Compensation of Revenue |
7.14% | — | — | — | |
Interest Coverage |
(78.28) | — | — | — | |
Operating CF/Net income |
1.97 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.54 | 0.65 | 0.67 | — | |
Capex/Depreciation |
(1.44) | (1.06) | (1.38) | — | |
Revenue per Share |
1.44 | 0.00 | — | 0.00 | |
Operating CF per Share |
(1.66) | (8.07) | 0.00 | 0.00 | |
Capex per Share |
(0.18) | (0.59) | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.00 | 0.00 | — |
Columns are period end dates